Ultra-Long Peripheral Catheter Versus Accelerated Seldinger Technique Long Peripheral Catheter in Difficult IV Access Patients

NCT ID: NCT07005310

Last Updated: 2025-06-05

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

NOT_YET_RECRUITING

Clinical Phase

NA

Total Enrollment

100 participants

Study Classification

INTERVENTIONAL

Study Start Date

2025-07-01

Study Completion Date

2026-04-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The aim of this study is to perform a comparative analysis of clinical outcomes associated with the use of an ultra-long peripheral catheter using (catheter-over-the-needle technique) versus an AST-long peripheral catheter in adult patients with difficult intravenous access (DIVA) in a real-world clinical setting. Specifically, the study will assess potential benefits, including longer mean catheter dwell time and improved catheter usability, as well as potential harms, such as increased incidence of catheter-related thrombosis, infections, phlebitis, infiltration, and unplanned catheter removal.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Difficult Intravenous Access Adults

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

DIAGNOSTIC

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Accelerated seldinger technique LPC

One study arm will be assigned the AST-long peripheral catheter (Powerglide Pro long peripheral catheter, BD) available in 18G 100 mm, 20G 100 mm (approx. 3.94 inches) and 22G 80 mm (approx. 3.15 inches).

Group Type ACTIVE_COMPARATOR

Powerglide pro™

Intervention Type DEVICE

A long peripheral catheter will be placed under ultrasound guidance. This catheter will be placed by using the Accelerated seldinger technique.

Ultra-long peripheral catheter

The other study arm will be assigned the ultralong peripheral catheter (Introcan Safety deep access catheter, B. Braun) available in 18, 20 and 22G and 63.5 mm (approx. 2.5 inches) in length.

Group Type EXPERIMENTAL

Introcan safety deep access

Intervention Type DEVICE

The catheter will be placed using ultrasound guidance and by using the 'catheter-over-the needle' approach.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Powerglide pro™

A long peripheral catheter will be placed under ultrasound guidance. This catheter will be placed by using the Accelerated seldinger technique.

Intervention Type DEVICE

Introcan safety deep access

The catheter will be placed using ultrasound guidance and by using the 'catheter-over-the needle' approach.

Intervention Type DEVICE

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Adult inpatients with DIVA, requiring placement of a long peripheral catheter, will be included in the study.
* A digital request form for venous access must be completed by the treating physician at the ward.
* Patients must be proficient in either Dutch or French
* Patients must have decision-making capacity or be represented by a legal representative.

Exclusion Criteria

* Expected therapy duration of less than 24 hours
* pregnancy
* Need for central venous access
* Inability to locate a deep peripheral vein in the upper extremity prior enrollment in the study
* Veins located deeper than 1.6cm prior enrollment in the study
* withdrawal of consent, or presentation at a time when study personnel are unavailable.
Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

University Ghent

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Tim Torsy

Prof. Dr.

Responsibility Role PRINCIPAL_INVESTIGATOR

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Universitair ziekenhuis Brussel

Brussels, Jette, Belgium

Site Status

Countries

Review the countries where the study has at least one active or historical site.

Belgium

Facility Contacts

Find local site contact details for specific facilities participating in the trial.

Wouter Pieteraerens

Role: primary

024763840

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

ONZ-2024-0303

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.

Evaluation of Accuvein in Adult Patients
NCT01020461 TERMINATED PHASE4